Skip to content
Targeting Solid Tumors with Oncolytic Viruses episode artwork

Oct 20, 2021 38 min

Targeting Solid Tumors with Oncolytic Viruses

from The Bio Report Hosted by Levine Media Group

As the treatment of cancers has moved toward an increasing emphasis on the role the immune system can play in fighting tumors, a range of new ways to enlist and train the immune system have emerged. Candel Therapeutics is developing oncolytic viral immunotherapies, which it says combines anti-tumor activity while also stimulating the immune system. We spoke to Paul Peter Tak, president and CEO of Candel Therapeutics, oncolytic viral immunotherapies, how they work, and why they may be able to bring benefits to the treatment of a range of solid tumors.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Targeting Solid Tumors with Oncolytic Viruses

0:00 38:12

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of The Bio Report?

This episode is 38 minutes long.

When was this The Bio Report episode published?

This episode was published on October 20, 2021.

Can I download this The Bio Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.